News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
TradingView Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article reports that Cingulate Inc. filed a Form 8K on August 13. The filing is brief and does not provide specific details about the content of the Form 8K. It notes that the information
Cingulate Inc. reported its Q2 2026 financial results, showing no product revenue and a net loss of $5.87 million, an increase from $4.98 million in the prior-year quarter. Key business developments include receiving an FDA complete response letter for CTx-1301 requesting additional CMC data, …
Cingulate Inc. reported a net loss of $5.9 million for the second quarter of 2026, with cash and cash equivalents totaling $28.4 million. The company is preparing for a resubmission of its CTx-1301 ADHD treatment NDA following an FDA Complete Response Letter. Cingulate anticipates …
Cingulate reported its second-quarter 2026 financial results, showing $28.4 million in cash and cash equivalents and a net loss of $5.9 million. The company expects its cash runway to extend into mid-2027 as it progresses with NDA resubmission work for CTx-1301 and builds commercial …
Cingulate Inc. (NASDAQ:CING) reported a net loss of $5.9 million for Q2 2026 and announced plans to resubmit its New Drug Application for CTx-1301, an ADHD treatment, after receiving a Complete Response Letter from the FDA requesting additional chemistry, manufacturing, and controls information. The …
Cingulate Inc. reported its second-quarter 2026 financial results, highlighting $28.4 million in cash and cash equivalents, expected to fund operations into mid-2027. The company is advancing its CTx-1301 ADHD drug toward NDA resubmission following an FDA Complete Response Letter and secured a new U.S. …
Cingulate Inc. (NASDAQ: CING) announced the publication of peer-reviewed data in CNS Drugs detailing the pharmacokinetic profile of its lead ADHD product candidate, CTx-1301. The study demonstrated that CTx-1301 provides rapid initial dexmethylphenidate exposure comparable to existing treatments, but crucially maintains statistically higher plasma …
Cingulate (CING) is projected to report its Q2 2026 earnings before market open on Tuesday, August 18th, with analysts forecasting a loss of $0.63 per share and revenue of $167,000. The company previously missed Q1 2026 consensus estimates with a loss of $0.95 per …
Cingulate Inc. announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in CNS Drugs, showcasing the differentiated pharmacokinetic profile of its lead ADHD product candidate, CTx-1301. The study supports Cingulate’s Precision Timed Release™ (PTR™) platform, demonstrating rapid onset and extended medication …
This article provides the "Price to book forward" financial metric for Cingulate Inc. (NASDAQ: CINGW). It is presented as a snapshot from TradingView, indicating the period, value, and change percentage for this financial data point.
This article provides a financial overview of Cingulate Inc. (NASDAQ: CING), focusing on its revenue breakdown. It points to sections like "Fundamentals and stats," "Overview," "Statements," "Statistics," "Dividends," "Earnings," and "Segments" for detailed financial information. The content itself is very brief and seems to …
Cingulate Inc. announced the publication of its Phase 3 clinical trial results for CTx-1301, a treatment for ADHD, in the Journal of Child and Adolescent Psychopharmacology. The study demonstrated clinically meaningful improvements in ADHD symptoms with a favorable safety profile, reinforcing the potential of …
Cingulate announced the publication of Phase 3 trial results for its lead ADHD candidate, CTx-1301 (dexmethylphenidate HCl), in the Journal of Child and Adolescent Psychopharmacology. The study showed that all three tested doses of CTx-1301 significantly improved ADHD Rating Scale-5 scores compared to placebo, …
This article provides a technical analysis of Cingulate Inc (CING), detailing its performance based on various indicators and moving averages. It covers key metrics like MACD, RSI, and different moving average values (MA5, MA10, etc.), summarizing the current signals as "Neutral" based on a …
This page provides financial data for Cingulate Inc. (NASDAQ: CINGW), specifically its enterprise value to EBITDA forward. It notes that the market is currently closed with no trades. The content briefly touches on various market data services and TradingView's offerings without providing detailed financial …
This article provides a detailed cash flow statement for Cingulate Inc (CING), including operating, investing, and financing cash flows presented quarterly and annually. It also includes key financial figures and answers frequently asked questions about different types of cash flow and their significance for …
This article provides the quarterly and annual income statements for Cingulate Inc. (CING), detailing key financial metrics such as operating expenses, R&D expenses, operating profit, and net income over several fiscal years and quarters. It also includes an FAQ section explaining how to read …
This article provides a detailed balance sheet for Cingulate Inc (CING), presenting quarterly and annual financial data spanning several years for various asset, liability, and equity categories. It allows users to evaluate the company's financial health, analyze fundamentals, and calculate key ratios. The article …
This article provides a basic overview of Cingulate Inc. (NASDAQ: CINGW) on TradingView, covering its market information, financials, and various data points accessible on the platform. It indicates that the market is closed with no trades and lists categories like fundamentals, statements, and segments.
This article provides an earnings forecast for Cingulate Inc (CING), highlighting analyst ratings, price targets, and past and future EPS expectations. Based on 4 analysts, the stock has a "Buy" rating with a target price of $23.00, representing a potential upside of over 375%. …
This article focuses on the enterprise value to EBIT forward ratio for Cingulate Inc. (NASDAQ: CINGW). It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics. The page includes information about market data providers and copyright …
Cingulate Inc. (NASDAQ: CING) announced the elimination of its Chief Legal Officer position, effective July 17, 2026. As a result, Nilay Patel will depart the company as an officer on August 3, 2026, with his termination classified as "without cause." The company does not …
This article summarizes Cingulate's registration filing, detailing its biopharmaceutical business model which uses proprietary Precision Timed Release (PTR) technology for ADHD and anxiety medications. The company, an emerging growth entity, reported 11,594,679 shares outstanding as of March 13, 2026, with plans to issue up …
This article reports on a Form 4 filing for Cingulate Inc. (CING) on July 21st, 2026. Form 4 filings disclose transactions by company insiders, but the article provides no specific details about the nature of the transaction. The ticker CING is noted to be …
Search by ticker symbol or company name and select a result to open its chart.